Hodges K B, Larson R S, Butler M G
Department of Pathology, Lewis-Gale Clinic, Salem, VA 24153, USA.
Ann Clin Lab Sci. 1998 Sep-Oct;28(5):293-9.
Chromosome fragile site or lesion data were examined in 154 institutionalized mentally retarded males with or without seizures or treated with anti-seizure medication. Blood lymphocytes were cultured using three different cell culture conditions and the incidence of specific chromosome fragile sites (10q25, 16q22, and 12q23) or lesions determined. Increased fragile sites were seen in mentally retarded males with seizures compared to those without seizures in cells grown in folate-deplete Medium 199. Those with seizures and treated with diphenylhydantoin had a higher incidence of induced fragile sites (p < 0.001) relative to similar patients treated with anti-seizure medication other than diphenylhydantoin. These results suggest that a cohort of patients with mental retardation and seizures are more likely to have induced cytogenetic changes when treated with diphenylhydantoin than mentally retarded individuals without seizures.
对154名入住机构的男性智障患者进行了染色体脆性位点或病变数据检查,这些患者有或无癫痫发作,或接受了抗癫痫药物治疗。使用三种不同的细胞培养条件培养血液淋巴细胞,并确定特定染色体脆性位点(10q25、16q22和12q23)或病变的发生率。在叶酸缺乏的199培养基中生长的细胞中,与无癫痫发作的智障男性相比,有癫痫发作的智障男性可见脆性位点增加。与接受除苯妥英钠以外的抗癫痫药物治疗的类似患者相比,癫痫发作且接受苯妥英钠治疗的患者诱导脆性位点的发生率更高(p<0.001)。这些结果表明,与无癫痫发作的智障个体相比,一组患有智障和癫痫发作的患者在接受苯妥英钠治疗时更有可能发生诱导性细胞遗传学改变。